Join Now

Author Archives: Natalie Themm

CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

UCLA research team has successfully created 7 pre-clinical monoclonal antibody candidates for targeting Ewing sarcoma

Posted in BioUtah News | Tagged | Comments Off on CancerVAX Reports Positive Progress on Kids Cancer Immunotherapy Treatment

FDA Issues Final Guidance on Content of Premarket Submissions for Device Software Functions

On June 13, the U.S. Food and Drug Administration (FDA) issued the final guidance: Content of Premarket Submissions for Device Software Functions. The final guidance provides information regarding the recommended documentation sponsors should include in premarket submissions for the FDA’s evaluation of the safety and effectiveness of device software functions. The guidance replaces the FDA’s […]

Posted in BioUtah News, Federal News | Comments Off on FDA Issues Final Guidance on Content of Premarket Submissions for Device Software Functions

Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled

Recursion’s small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5.

Posted in BioUtah News | Tagged | Comments Off on Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and response

Posted in BioUtah News | Tagged | Comments Off on Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

Vistim Labs Closes First Round of Funding

Vistim Labs Closes First Round of Funding

Posted in BioUtah News | Tagged | Comments Off on Vistim Labs Closes First Round of Funding

Culmination Bio and Cofactor Genomics Leverage Largest Biobank in the U.S. for PREDAPT Precision Medicine Clinical Trial

Respective leaders in healthcare innovation and RNA diagnostics team up to identify patients who will benefit from immunotherapy

Posted in BioUtah News | Tagged | Comments Off on Culmination Bio and Cofactor Genomics Leverage Largest Biobank in the U.S. for PREDAPT Precision Medicine Clinical Trial

NexEos Bio Names Dawn Rubel as President, Research and Development

NexEos Bio today announced that Dawn Rubel has joined the Company as President, Research and Development.

Posted in BioUtah News | Tagged | Comments Off on NexEos Bio Names Dawn Rubel as President, Research and Development

NUSANO TO PRESENT PRODUCTION CAPABILITIES TO EUROPEAN RADIOPHARMACEUTICALS WORKING GROUP

PROPRIETARY ION SOURCE AND BEAM TECHNOLOGY CAPABLE OF PRODUCING APPROXIMATELY 10 TIMES THE CURRENT GLOBAL SUPPLY OF ASTATINE-211

Posted in BioUtah News | Tagged | Comments Off on NUSANO TO PRESENT PRODUCTION CAPABILITIES TO EUROPEAN RADIOPHARMACEUTICALS WORKING GROUP

Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies

Thermo Fisher Scientific Opens Cell Therapy Facility at UCSF to Accelerate Development of Breakthrough Therapies

Posted in BioUtah News | Tagged | Comments Off on Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies

Intermountain Health Launches Culmination Bio

Intermountain Health announced the launch of Culmination Bio, a biotech company developing an exclusive, anonymized, and de-identified intelligence platform.

Posted in BioUtah News | Tagged | Comments Off on Intermountain Health Launches Culmination Bio

Still on the Hill…

BioUtah continues to monitor issues of importance to our industry and engage with legislators on Utah’s Capitol Hill.

Posted in BioUtah News | Tagged | Leave a comment

R-Zero Raises $105 Million Series C to Improve the Indoor Air We Breathe

R-Zero’s UV-C Technology Improves Indoor Air Quality for Millions of People; Reduces Reliance on HVAC Systems and Chemicals that Harm Environment

Posted in BioUtah News | Tagged | Leave a comment